Engage and Network with 600+ Experts Pioneering the Gene Therapy Field
The therapeutic potential of gene therapies is clear, but in order for this potential to be realized, lessons and key insights from the companies who are directly involved in cutting edge development work must be shared and disseminated.
Established now as the industry-leading event for companies developing gene therapies in the rare disease space, the specific focus of the conference means it is an unparalleled opportunity to engage in meaningful discussion with 600+ experts at the forefront of this field.
200+ organizations joined us at the meeting in March 2019, including:
4D Molecular Therapeutics – Abeona – Absorption Systems – Akouos – ARM – Amicus – Apic Bio -Audentes – AveXis AVROBIO - Axovant Sciences -Bayer – Benitec – BIA Separations – Biogen - BioMarin - Celgene – Covance – CSL Behring Delphi Genetics – Editas Medicine – Express Scripts – EyeKor – FDA - Flexion Therapeutics – Genentech – Immusoft Johnson & Johnson – LogicBio – Lonza – Lysogene – Merck – MIT – Moderna – Mustang Bio – NORD – Neurogene- Nightstar – Ophthotech – Orchard – Pall – Pfizer – Polyplus Transfection – PPD – Prevail Therapeutics – Project Farma – QPS REGENXBIO – Rho – Sangamo – Sanofi – Sarepta – Solid Bio – Spark Therapeutics – Takeda – Treximo – UCB – Ultragenyx uniQure – Vertex – ViGene – Vivet – Voyager
Interactive sessions built into the main agenda provide extensive opportunities for cross-functional collaboration where you can benchmark your progress and critically evaluate your development and commercialization strategies.
Leave with clear and actionable insights that will prepare you for a year of unprecedented progress in the field.
“This is "the conference" to attend for professionals that are already involved or about to embark in the gene therapy space. All of the relevant experts in their field are represented and available to share their knowledge and experience. A true educational and networking event!”
Bill White, AveXis
“This is the place to go to if you want to connect to experts in the field of gene therapy.”
Hanspeter Rottensteiner, Shire